Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir

Curtis Cooper, Susanna Naggie, Michael Saag, Jenny C. Yang, Luisa M. Stamm, Hadas Dvory-Sobol, Lingling Han, Phillip S. Pang, John G. McHutchison, Douglas Dieterich, Mark Sulkowski

Research output: Contribution to journalArticlepeer-review

Abstract

We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed. Clinical Trials Registration. NCT02073656.

Original languageEnglish (US)
Pages (from-to)528-531
Number of pages4
JournalClinical Infectious Diseases
Volume63
Issue number4
DOIs
StatePublished - Aug 15 2016

Keywords

  • Direct-acting antiviral agents
  • HCV NS5B polymerase inhibitor
  • HCV/HIV coinfection
  • NS5A resistance
  • Re-treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir'. Together they form a unique fingerprint.

Cite this